Articles related to VACCINES
COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022
In this cross-sectional study of US adults hospitalized with COVID-19 during January 2022 to April 2022, hospitalization rates from COVID were 10.5 times higher in unvaccinated persons and 2.5 times higher in vaccinated persons with no booster dose, respectively, compared with those who had received a booster dose.
Allergy & Immunology September 20th 2022
ACIP: Updated Vaccine Guidance for the 2022-2023 Influenza Season
All vaccines are expected to be quadrivalent. Included in the update are expanded approval for Flucelvax Quadrivalent, administration adjustments for Afluria Quadrivalent, and higher dose vaccines for those 65 years old and older.
All Specialties September 13th 2022
Risk for Myocardial Infarction (MI), Stroke, and Pulmonary Embolism (PE) Following COVID-19 Vaccines in Adults Younger Than 75 Years in France
To assess short-term risk for severe cardiovascular events (excluding myocarditis and pericarditis) after COVID-19 vaccination, adults younger than 75 years hospitalized for PE, acute MI, hemorrhagic stroke, or ischemic stroke (73,325 events) were reviewed in relation to a 1st or 2nd COVID vaccine dose. No association was found between the Pfizer–BioNTech or Moderna vaccine and severe cardiovascular events. The first dose of the Oxford–AstraZeneca vaccine was associated with acute MI and PE in the second week after vaccination. An association with MI in the second week after a single dose of the Janssen vaccine could not be ruled out.
Cardiology September 6th 2022
How Well Does the Monkeypox Vax Work? No One Knows for Sure
An efficacy number that’s been widely and unquestioningly quoted by various media organizations — “85% effective” or “at least 85% effective” — is based entirely on a small study done in Africa in the 1980s that has major limitations and with “pretty weak” findings.
Family Medicine/General Practice August 10th 2022
Does Anti-CD20 Treatment Affect Response to COVID-19 Vaccines in Patients With Multiple Sclerosis? Review of a Pilot Study
In this Journal Club discussion, among participants in the vaccine-CD20-vaccine cohort, 100% of participants experienced a measurable response to a third dose of a COVID-19 vaccine compared with 18% in the CD20-vaccine cohort.
Neurology July 12th 2022